Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis Sees Opportunities In Financial Crisis, CEO Tells Tokyo Business Group

This article was originally published in PharmAsia News

Executive Summary

TOKYO - Novartis CEO Daniel Vasella told an audience in Tokyo last week that "the current [global financial] situation creates opportunities because [Novartis has] a very solid free cash flow and most [Novartis] companies have a solid free cash flow and are not in a highly indebted environment.

You may also be interested in...



Novartis Japan Looks To Capitalize On Drug Approval Spurt, Submits NDA For Everolimus

Product launches will follow listing by Japan’s Central Social Insurance Medical Council.

Novartis Japan Looks To Capitalize On Drug Approval Spurt, Submits NDA For Everolimus

Product launches will follow listing by Japan’s Central Social Insurance Medical Council.

Novartis Japan Looks To Capitalize On Drug Approval Spurt, Submits NDA For Everolimus

Novartis Japanese subsidiary Novartis Pharma KK announced Jan. 21 four new drug approvals from Japan's Ministry of Health, Labor and Welfare. The new drugs are approved to treat asthma, hypertension, cancer and age-related macular degeneration

Related Content

UsernamePublicRestriction

Register

ID014775

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel